Evotec Becomes the First Contract Research Facility in Europe to Offer Agilent's RapidFire/MS Screening for Pharmaceutical Drug Discovery


Hamburg, Germany - 16 May 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) is proud to announce the addition of Agilent Technologies' RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg.

RapidFire, a robust, in-line solid phase extraction technology enables ultrafast, direct analysis of native compounds for a wide variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec is the first Pharmaceutical Contract Research Organisation in Europe to offer these services. The Evotec facility in Hamburg will be equipped with state-of-the-art technology from Agilent including multiple RapidFire High-throughput Mass Spectrometry Systems and 6460 Triple Quadrupole instrumentation.

'Evotec is the ideal partner for Agilent Technologies as we expand this industry-leading platform into the European Contract Research market,' said Gustavo Salem, Agilent Vice President and General Manager, Biological Systems Division. 'Evotec's leadership role as a drug discovery service provider will ensure that this market is exposed to the capabilities of Agilent's RapidFire and gold-standard Mass Spectrometry platforms.'

Mario Polywka, Chief Operating Officer for Evotec commented: 'The addition of Agilent's RapidFire Mass Spectrometry analysis instrumentation and capabilities is a tremendous boost to Evotec's best in class screening platform. Working with Agilent will ensure that these systems are brought into operation quickly and that our partners and collaborators will benefit from further efficiencies in lead discovery.'